Lilly signs OmniAb ion channel discovery deal with up to $370 million in milestones
- nuaxia
- 2 days ago
- 2 min read
The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.
Eli Lilly and OmniAb have entered a global collaboration and licence agreement for a new ion channel programme, with OmniAb receiving an undisclosed upfront payment and becoming eligible for up to $370 million in research, development and commercial milestones plus tiered royalties on global net sales.
The partnership applies OmniAb’s discovery platform and specialist ion channel capabilities to a new programme, although the companies have not disclosed the therapeutic target, modality or disease area.
Field | Content |
Alert Type | Deal |
Companies | Eli Lilly and Company; OmniAb |
Deal Type | Global collaboration and licence agreement |
Asset or Company | New undisclosed ion channel discovery programme |
Technology or Modality | Ion channel drug discovery and screening; specific therapeutic modality undisclosed |
Deal Value | Undisclosed upfront payment, plus up to $370 million in research, development and commercial milestone payments and tiered royalties on global net sales. The $370 million represents contingent milestones and is not guaranteed consideration. |
Development Stage | Discovery |
Geography | Global |
What Happened | On 17 August 2026, OmniAb announced a global collaboration and licence agreement with Eli Lilly for a new ion channel programme. Lilly gains access to OmniAb’s technology platform and expertise in ion channel discovery and screening. OmniAb will receive an undisclosed upfront payment and is eligible for up to $370 million in research, development and commercial milestones, plus tiered royalties on global net sales. The therapeutic target, modality and disease indication have not been disclosed. |
Why It Matters | Ion channels are important but technically challenging drug targets because their membrane-bound structures can complicate antigen generation, screening and discovery. The agreement gives Lilly access to OmniAb’s specialist ion channel capabilities while providing OmniAb with another externally funded application of its discovery technology, although the programme is too early and insufficiently disclosed to assess its therapeutic potential. |
Supporting Context | OmniAb’s wider discovery platform combines engineered transgenic animals, computational antigen design and high-throughput screening capabilities. Its technology is designed to support discovery against challenging targets, including multi-transmembrane proteins such as ion channels. |
Strategic Rationale | Lilly gains access to specialised ion channel discovery and screening expertise for an undisclosed programme, while OmniAb receives upfront economics and retains milestone and royalty participation if a resulting programme progresses through development and commercialisation. |
Potential Impact | Successful progression could provide further validation of OmniAb’s ion channel discovery capabilities and generate milestone and royalty income, but the potential clinical or commercial impact cannot yet be assessed because the target, modality and indication remain undisclosed. |
Key Takeaway | Lilly is putting up to $370 million in contingent milestones behind an OmniAb-enabled ion channel discovery programme, with the underlying therapeutic opportunity remaining undisclosed. |
What to Watch | Disclosure of the therapeutic target, modality or disease area and whether the programme progresses from discovery into preclinical and clinical development. |
Primary Source | |
Relevant Date | 17 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments